KLRD1 (CD94):在头部和部状细胞癌中是一种预后生物标志物和治疗候选物
Chengyuan Dong1, Ziyou Lin2, Yunzhao Hu1
1Shanghai TCM-Integrated Hospital, Shanghai university of TCM, Shanghai, China.
Journal of Cancer
|January 9, 2025
概括
杀伤细胞莱克类受体D1 (KLRD1) 是头部和部状细胞癌 (HNSC) 的关键预后标志物. 它的表达影响抗瘤免疫力,并表明个性化免疫疗法策略的潜力.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 基因组学就是基因组学.
背景情况:
- 杀手细胞莱克类受体D1 (KLRD1) 是抗瘤免疫的组成部分.
- 对于KLRD1在各种癌症,患者预后和免疫治疗潜力的作用,需要进一步阐明.
研究的目的:
- 在各种癌症中全面分析KLRD1表达模式.
- 研究KLRD1的预后意义及其与瘤免疫微环境的关联.
- 评估KLRD1作为免疫治疗的潜在治疗点.
主要方法:
- 从TCGA,GTEx和GEO数据库进行多主题数据分析.
- 单细胞RNA测序以评估KLRD1在免疫细胞中的表达 (NK和CD8Tex).
- 功能丰富 (GO,KEGG),免疫透 (CIBERSORT),癌症免疫周期和药物敏感性分析.
主要成果:
- KLRD1在各种癌症中显示出显著的差异表达和预后价值,特别是在头部和部状细胞癌 (HNSC) 中.
- 在NK和CD8Tex细胞中高KLRD1表达突出了其在抗瘤反应中的作用.
- KLRD1与免疫细胞透,增强免疫活性和对HNSC细胞分裂抑制剂的敏感性相关.
结论:
- 在HNSC中,KLRD1作为一个关键的独立预后生物标志物.
- KLRD1代表了开发针对HNSC的个性化免疫疗法的有希望的目标.
更多相关视频
11:28Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics
Published on: May 11, 2016
8.5K
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
17.8K
相关概念视频
lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
